beth levant, ph.d., m.p.a.wichita.kumc.edu/documents/pharmacology/faculty/levant...beth levant,...

Beth Levant, Ph.D., M.P.A.

Work Address: Department of Pharmacology, Toxicology, and Therapeutics University of Kansas Medical Center, MS-1018 3901 Rainbow Boulevard Kansas City, Kansas, 66160-7417 U.S.A. Telephone (913) 588-7527 FAX (913) 588-7501 e-mail [email protected] Education and Training: 2002 Master of Public Administration, Health Services Administration and Higher Education emphases

Bloch School of Business and Public Administration, University of Missouri, Kansas City, MO 1991-1993 Postdoctoral Fellowship, Neuropharmacology The DuPont Merck Pharmaceutical Company, Wilmington, Delaware Mentor - Errol B. De Souza, Ph.D. 1990 Doctor of Philosophy, Pharmacology Duke University, Durham, North Carolina Mentor - Charles B. Nemeroff, M.D., Ph.D. Dissertation: Studies on the mechanism underlying antipsychotic drug-induced alterations in regional brain neurotensin concentrations. 1985 Bachelor of Science, Zoology University of California - Davis, Davis, California Research Interests:

Role of polyunsaturated fatty acids in neuronal functional and neuropsychiatric disorders, and drugs and diseases affecting the CNS dopamine systems. Major research foci are the role of brain polyunsaturated fatty acid composition in postpartum depression, and the role of developmental docosahexaenoic acid deficiency in attention deficit-hyperactivity disorder, schizophrenia, traumatic brain injury, and Parkinson’s disease. Additional interests include the D3 dopamine receptor as a therapeutic target for schizophrenia, drug addiction, and Parkinson’s disease; and mechanisms underlying sensitization to psychostimulants.

Professional Experience: Current Professor with Tenure, Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS. Assistant Professor (8/93-6/99). Associate Professor (7/99-6/12) (Primary appointment).

Scientist, Kansas Intellectual and Developmental Disabilities Research Center (formerly the Smith Mental Retardation Research Center), University of Kansas Medical Center, Kansas City, KS. Associate Scientist (7/99-6/12). Assistant Scientist (5/95-6/99). (Joint appointment).

12/01-12/03 Research Pharmacologist, Veterans’ Administration Medical Center, Kansas City, MO. (Joint appointment).

1/91 - 6/93 Postdoctoral Fellow, Central Nervous System Diseases Research, The DuPont Merck Pharmaceutical Company, Wilmington, DE.

8/85 - 12/90 Predoctoral Fellow, Department of Pharmacology, Duke University, Durham, NC.

Beth Levant, Ph.D./2 August 4, 2015

4/85 - 7/85 Research Laboratory Technician, Pharmacology, Syntex Corporation, Palo Alto, CA.

1/85 - 3/85 Student Intern, Pharmacology, Syntex Corporation, Palo Alto, CA.

3/84 - 12/84 Pharmacology Research Intern, Department of Pharmacology, University of California, Davis, CA.

9/83 - 8/84 Laboratory Assistant, Department of Zoology, University of California, Davis, CA.

1/83 - 8/83 Laboratory Assistant, Department of Botany, University of California, Davis, CA.

Misc. Training/Professional Development:

Radiation Safety Training Seminar (8 hrs). E.I. DuPont de Nemours & Co., Inc., Wilmington, DE, Sept. 19, 1991.

HPLC Basics School with Electochemical Detector Theory. ESA Biosciences, Inc., Chelmsford, MA, Aug. 21-23, 2007.

Association of American Medical Colleges (AAMC) Mid-Career Faculty Professional Development Seminar. Scottsdale, AZ, Dec. 6-9, 2008.

Science: Becoming the Messenger. National Science Foundation, Lawrence, KS. Jan. 27, 2011.

Leadership Academy, University of Kansas Medical Center, 2012-2014

Essential Skills in Medical Education (ESME), International Association of Medical Science Educators, June 12-16, 2015.

Grants and Contracts:

Current

Lied Endowed Basic Science Research Grant: 24S-Hydroxycholestorol, a Potential Diagnostic Marker of Traumatic Brain Injury, Principal Investigator. 2/1/13 - 1/31/14. $30,000 DC. 10% effort (unfunded).

National Institute on Drug Abuse: Potent and Selective D3 Partial Agonists for the Treatment of Cocaine Abuse (R01 DA032943; PI: Shaomeng Wang). Co-Investigator. 2/1/12 - 1/30/15 Subcontract $185,460 DC. 15% effort.

National Institutes of Health: Nuclear Receptors in Liver Health and Disease. (P20 GM103549; PI: Hartmut Jaeschke) Key Personnel (Mentor to junior investigators). 6/1/11 – 5/31/16 $1,499,831 DC. 4 % effort.

National Institute on Child Health and Human Development: Training Program in Neurological and Rehabilitation Sciences (T32 HD057850; PI: Randolf Nudo). Key Personnel (Faculty). 4/1/08 – 4/30/19. $216,887 DC. 0% effort.

National Institute of Environmental Health Sciences: Training Program in Environmental Toxicology. (T32 ES007079; PI: Bruno Hagenbuch) Key Personnel (Faculty). 7/1/06 - 6/30/16 $536,232 DC. 2% effort (unfunded)

National Institute of Child Health and Human Development: Kansas BIRCWH Career Development Program in Women’s Health. (K12 HD052027; PI: Patricia A. Thomas). Key Personnel (Mentor to junior investigators). 9/1/05 - 8/30/15 $3,312,500 DC. 0% effort.


Previous National Institutes of Health: Center for Molecular Analysis of Disease Pathways. Project 4: Neurotransmitter

Interactions of Sub Second Timescales (P20 GM103638; PI: Susan Lunte/Michael Johnson, Project 4) Co-Investigator. 7/1/12-6/30/15. $25,000 DC. 5% effort.

National Instite on Neurological Diseases and Stroke: N-3 Fatty Acids: Roles in Parkinson’s Disease (R21 NS067422). $275,000 DC. Principle Investigator. 7/1/10 - 4/30/12 (no-cost extension to 4/30/13). $275,000 DC. 12.5% effort.

National Institute of General Medical Sciences: Short Course: Integrative and Organ Systems Pharmacology (R25 GM074089; PI: Myrons Toews). Key Personnel (Instructor). 5/1/05 - 4/30/13 $1,200,000 DC. 0% effort.

National Institute on Drug Abuse: Design, Synthesis and Characterization of Dopamine Receptor 3 Ligands (R01 DA020669; PI: Shaomeng Wang). Co-Investigator. 8/10/06 - 5/31/11 (no-cost extension to 5/31/12) Subcontract $304,344 DC. 15% effort.

National Institute on Child Health and Human Development: N-3 Fatty Acids and Outcomes in Pediatric Traumatic Brain Injury (R03 HD059939). Principal Investigator. 12/22/08 – 11/30/10 (no-cost extension to 11/30/11). $100,000 DC. 10% effort.

KUMC Training Program in Biomedical Research Fellowship. (Awardee: Kristin L. Russell) Sponsor. 7/1/10 - 6/30/12 $11,500 DC. 0% effort. (2nd year not activated)

Lied Endowed Basic Science Research Grant: N-3 Fatty Acids: A Risk Factor in Parkinson’s Disease? Principal Investigator. 4/2/09 - 6/30/10 $25,000 DC. 10% effort (unfunded).

Kansas IDeA Research Excellence (K-INBRE) Faculty Scholar Award. University of Kansas Medical Center, Kansas City, KS 2006-2007. $25,000.

National Institutes of Health: Nuclear Receptors in Liver Health and Disease. (P20 GM103549; PI: Curtis D. Klaassen) Key Personnel (Mentor to junior investigators). 6/1/06 - 4/30/11 $1,499,831 DC. 4 % effort.

National Institute of Mental Health: Brain DHA, Dopamine, and Behavior: Roles in ADHD (R01 MH067938). Principal Investigator. 9/30/04 - 6/30/07 (no-cost extension to 6/30/08) $405,000 DC. 25% effort.

National Institute of Mental Health: Brain LC-PUFAs and Maternal Mental Health (R01 MH071599). Principal Investigator. 9/15/04 - 6/30/07 (no-cost extension to 6/30/08) $475,000 DC. 25% effort.

Kansas Biomedical Research Infrastructure Network (K-BRIN, P20 RR016475) Summer Research Scholarship. (Awardee: Lauren Reed) Sponsor. Summer 2004. $3,000. 0% effort.

Kansas Biomedical Research Infrastructure Network (K-BRIN, P20 RR016475) Pilot Grant: Neural Mechanisms of Restless Legs in a Rodent Model. Principal Investigator. 12/15/03 - 6/30/04 $24,993, DC. 10% effort (unfunded).

Kansas University Medical Center Research Institute Bridging Grant: Brain DHA, Dopamine, and Behavior: Roles in ADHD. Principal Investigator. 11/21/03 - 9/30/04 $24,908 DC. 10% effort (unfunded).

KUMC Training Program in Biomedical Research Fellowship. (Awardee: Toni L. [Carpenter] Richards) Sponsor. 7/1/03 - 6/30/05 $22,950 DC. 0% effort.

Lied Endowed Basic Science Research Grant: Proteomics Approach to Drug Abuse and Mental Health. Principal Investigator. 3/1/03 - 2/28/04 $35,000 DC. (no-cost extension to 8/31/04) 10% effort (unfunded).

National Institute of Nursing Research: Diaphragm Fatigue: Mechanisms of Treatment with Dopamine (RO1 NR05317; PI: Janet Pierce). Co-Investigator. 3/1/02 - 2/28/05 (no-cost extension to 2/28/06) $675,000 DC. 10% effort.

Aventis Pharmaceutical Company: Testing of compounds for occupancy of the dopamine D3 receptor in rats. Principal Investigator. 6/27/01-6/26/02 $16,000 DC. 10% effort.


Pharmacia & Upjohn: D3 Dopamine Receptors in Mesencephalic Cell Cultures. Principal Investigator. 3/1/00 - 2/28/01 $10,000 DC. 10% effort.

Lied Endowed Basic Science Research Grant: Anatomical Substrates of Psychostimulant Sensitization. Principal Investigator. 2/1/00 - 1/31/01 $35,000 DC. (no-cost extension to 12/31/01). 10% effort (unfunded).

ASPET Dalton/Zannoni Summer Undergraduate Fellowship Program. Director. Summer 1999, $7,500 DC. 0% effort.

Medical Research Council of Canada: Dopamine, Movements, Motion and Behavior: Sensitization to Quinpirole. (P.I.: Henry Szechtman). Collaborator. 4/1/98 - 3/31/03 $208,310 DC. 10% effort (unfunded).

National Institute of Neurological Diseases and Stroke: Cellular Mechanisms of the D3 Dopamine Receptor. (F32 NS10637; P.I.: Rose A. Shafer) Sponsor. 4/1/98-3/30/00 $70,000 (not activated). 0% effort.

National Institute of Child Health and Human Development: Rat Models of MR/DD and Risks of Aberrant Behavior (RO1 HD33896; PI: Richard E. Tessel). Co-Investigator. 8/1/96 - 7/31/00 $797,688 DC. 15% effort.

NARSAD Young Investigator Award: A Novel Binding Site for Monoamine Oxidase Inhibitors in Brain. Principal Investigator. 7/1/95 - 6/30/97 $60,000 DC. (no-cost extension to 6/30/98). 10% effort (unfunded).

National Institute of Mental Health: D3 Dopamine Receptors, a Potential Antipsychotic Target (R29 MH52839). Principal Investigator. 4/1/95 - 3/31/00 $349,904 DC. (no-cost extension to 3/31/01). 50% effort.

NIH Institutional Development Award: The Kansas IDeA: Redox Regulation of Bio-responses in Health and Disease. (P20 RR10256; PI: Thomas L. Pazdernik) Junior Investigator. 10/1/94 - 9/30/96 $107,586 DC. 10% effort.

Kansas University Medical Center Research Institute Interim Award: D3 Dopamine Receptors, a Potential Antipsychotic Target. Principal Investigator. 7/1/94 - 6/30/95 $24,957 DC. 10% effort (unfunded).

Pharmaceutical Research and Manufacturers of America Foundation, Inc.: In Vivo Pharmacology of 7-OH-DPAT in Brain. Principal Investigator. 1/1/94 - 12/31/94 $12,500 DC. 10% effort (unfunded).

Teaching and Supervisory Experience: Formal Instruction Duke University, Durham, NC Guest lecturer, Dept. of Psychology (4 lectures), Fall 1990. University of Kansas Medical Center, Kansas City, KS Seminar in Pharmacology (PHCL 809) – 1993 - present Molecular and Cellular Pharmacology (PHCL/PTOX 841), Section head, 1994; Co-director, 1996; Director, 1998. Neuropharmacology (PHCL 941) - 1995; Director, 1998. Medical Pharmacology (PHRM 850) - 1995-2007; Section head 2001-2006; Block head 2006-2007 Advanced Neuroscience (PHCL/PHSL/ANAT 846) - 1997-2000 Research Ethics - Program Coordinator and session leader - 1994-2011 Research Methods - 1996-1998 Pharmacology review for Neurology residents - 1995 Pharmacology of the Central Nervous System (PHCL 764) - 2000 Essentials of Pharmacology (PHCL 880) – 2000 – present (even years) Neuroendocrine Pharmacology (PHCL 912) - 2000 IGPBS Module 6 - Molecular and Physiological Basis of Disease I (PCHL/PHSL/ANAT 896) - 1998


IGPBS Module 5 - Molecular and Physiological Basis of Disease (PCHL/PHSL/ANAT 895) -1999 Neurochemistry for Psychiatry Residents – 2000 IGPBS Module 9 - Bioethics (PHCL 901), Director, 2002-2009 Medical Neuroanatomy (NEUS 840) – 2003-2004 Integration & Consolidation (CORE 860) – Section head, 2008-2011, Director, 2012-present Health and Social Behavior (HPM 858) – 2011 Neurorehabilitation Training Grant Research Ethics – 2013-present Kansas City University of Medicine and Biosciences, Kansas City, MO Neurosciences – 2002-2014

University of Nebraska Medical Center, Omaha, NE Integrated Organ System Pharmacology, NIH Short Course – 2005-2012

Medical Reserve Corps of Kansas City, Kansas City, MO IS-22: Are You Ready? An In-depth Guide to Citizen Preparedness - 2010-present

Supervision Department of Pharmacology, University of Kansas Medical Center, Kansas City, KS

Postdoctoral Fellows: Rebecca J. Flietstra, Ph.D. – 1996 Current position: Professor, Point Loma Nazarene University, San Diego, CA

Rose A. Shafer, Ph.D. - 1997 – 1998 Awarded NIH Individual Postdoctoral Fellowship (not activated) Current position: Homemaker

Joy (Tina) Ahlgren-Beckendorf, Ph.D .- 1998–1999 Current position: Assistant Professor, University of Mary Hardin-Baylor,

Belton, TX

Graduate Students: Sarah M. Gilliland - M.S., 1998 Current position: Nurse, Truman Medical Center, Kansas City, MO

Toni L. (Carpenter) Richards –Ph.D., 2006 Awarded KUMC Biomedical Research Training Program (BRTP) Fellowship

(2003-2005), ASPET Travel Award and ASPET Graduate Student Best Abstract, 2nd Place (2006).

Current position: Scientist, Plato Biopharma, Inc., Westminster, CO

Kristin L. Russell – Ph.D., 2013 Awarded KUMC Biomedical Research Training Program (BRTP) Fellowship

(2010-2011) and NIH Training Program in Neurological and Rehabilitation Science Fellowship (2011-2013).

Current position: Scientist, Xenometrics, LLC, Stilwell, KS

Michelle Healy Stoffel – Ph.D., 2013 Awarded Institute for Advancing Medical Innovation (IAMI) Fellowship

(2010-2012) and a Mabel A. Woodyard Fellowship for the Study of Neurodegenerative Disorders (2012-2013)

Current position: Pathology Resident, University of Wisconsin, Madison, WI

Graduate Student Rotations: Neda L. Nasseri (Leonard) - Fall, 1994 Jeffrey D. Moehlenkamp - Spring, 1995 Nichole R. Vansell - Spring, 1996 Sarah M. Gilliland - Spring, 1997 Lori Martin - Summer, 1997


Amy Mize - Summer, 1997 Toni L. Richards - Fall, 2000 Gregory Bomhoff – Fall, 2001 Nicholas McWilliams – Fall, 2003 Jennifer F. Crane – Fall, 2004 Jessica Ittner – Spring, 2005 Karra Jones (MD/PhD program) – Summer, 2005 Scott Reisman – Summer, 2005 David Guggenmos – Spring, 2006 Kristin L. Russell – Fall, 2007 Bliss Hartnett (MD/PhD program) – Summer, 2008 Michelle Healy (MD/PhD program) – Summer, 2008 Nichole Werbin – Summer, 2009

Undergraduate Interns: Gregory N. Bancroft - Summer, 1994, 1995 Christina M. Selkirk - Summer, 1995 Carmita A. Coleman - Summer, 1996 Emily A. White - Summer, 1997 Brian Wilson - Summer, 2000 Baiju Gandhi – Summer, 2001 Evan Gillespie – Summer, 2003 Joel Hake – Summer, 2004 Robert Chen – Summer, 2007 Katrina Kutchko – Summer, 2010 Patrick Gregg – Summer, 2012

Other Students: Ben Messer - Blue Valley High School intern, 1994-1995 Nathan Jewell - Summer, 1998 Lauren Reed – K-BRIN Summer Research Scholar, Summer, 2004 Taylor Kinney – Summer Medical Student, Summer 2012

Technicians: Kimberly A. Morgan - Research Associate – 1994-2000 Gregory N. Bancroft - Laboratory Technician - 1996 Nicholas J. Nielsen - Laboratory Assistant – 1996-1998 Timothy J. Albright – Laboratory Assistant – 2001-2002 Christopher Arnold – Laboratory Assistant – 2001 Aali Shah – Laboratory Assistant – Summer, 2003 Marlies Ozias, M.S. – Research Associate – 2004-2009 Keli Bolton – Laboratory Assistant – 2004-2005 Tiffany M. McBurney - Laboratory Assistant – 2005 Paul F. Davis – Research Assistant – 2005-2008 Michael Richards – Laboratory Assistant – 2005-2006 Lauren Reed – Laboratory Assistant – Summer, 2005 Audrey Atencio – Laboratory Assistant – 2005-2006 Benjamin Winter – Laboratory Assistant – Summer, 2006 Guillermo Lona – Research Assistant – 2006-2007 Heather Spalding – Research Assistant – 2008-present Andrew Ralya, Ph.D. – Research Assistant - 2012


Dissertation/Thesis Committees University of Kansas Medical Center, Kansas City, KS Alison J. Draper, Department of Pharmacology (Ph.D., Toxicology, 1996) Sarah M. Gilliland, Department of Pharmacology, Chair (M.S., Pharmacology, 1998) Mitchell Emerson, Department of Pharmacology (Ph.D., Pharmacology, 1999) Ning Deng, Department of Pharmacology (M.S., Toxicology, 1999) Claire R. Croutch, Department of Pharmacology (Ph.D., Toxicology, 2005) Vanja Duric, Department of Pharmacology (Ph.D., Pharmacology, 2006) Toni L. Richards, Department of Pharmacology, Chair (Ph.D., Pharmacology, 2006) Katryn Allen, Department of Pharmacology, (Ph.D., Pharmacology, 2011) Hyong-woo Bai, Department of Pharmacology, (Ph.D., Pharmacology, 2009) Ji-Hyuk Park, Department of Occupational Therapy Education, (Ph.D., Occupational Therapy Ed., 2010) Kristin L. Russell, Department of Pharmacology, Chair, (Ph.D., Pharmacology, 2013) Michelle Healy Stoffel, Department of Pharmacology, Chair, (Ph.D., Pharmacology, 2013) Andrew T. Ralya, Department of Pharmacology (Ph.D., Pharmacology, 2011) Clarence (Dave) Williams, Department of Pharmacology (Ph.D., Toxicology, 2012) Kayla Raider, Department of Physiology (M.S., 2014) Lu Jiange, Department of Pharmacology (2015-present) University of Kansas, Lawrence KS Guanghui Wang, Department of Pharmacology and Toxicology (Ph.D., 2000) Brenda Birkestrand Smith, Department of Pharmacology and Toxicology (Ph.D., 2002) Laura Mosher, Department of Pharmacology and Toxicology (2014-present) External Thesis Examiner Michelle L. Perrault, McMaster University, Hamilton, ON, Canada (Ph.D. , 2007) Institutional Service:

DuPont Merck Pharmaceutical Company, Wilmington, DE DuPont Merck Postdoctoral Program Advisory Board (1991-1993) Career Development Committee - DuPont Merck Postdoctoral Program (1991-1993) University of Kansas Medical Center, Kansas City, KS Department of Pharmacology Faculty Search Committee (1994-1995; 1996-1997; 2003-2007) Graduate Curriculum Review Committee (1994-1995; 1997) Graduate Education Committee (1997-2000, Chair 1999-2000) Director, Summer Undergraduate Internship Program (1997-1999) Director, Graduate Recruiting (1998-1999) Seminar Co-director (2002-2003) Seminar Committee, Chair (2011-present) Promotion & Tenure Committee (2012-present)

Graduate School Graduate Travel Committee (1996-1999) Interdisciplinary Graduate Core Curriculum Committee (1996) Interdisciplinary Graduate Core Curriculum Subcommittees for Blocks 2, 3, 4 and 6 (1996) Neuroscience Graduate Course Planning Committee (1996) Neuroscience Program Advisory Committee (1997-2001) Judge, Student Research Forum (1994-2011)


Graduate Council (1999-2000) Standing Committee for Fellowships, Scholarships, and Student Affairs (1999-2000) Interdisciplinary Graduate Program in the Biomedical Sciences Advisory Committee (1999-2000) Interdisciplinary Graduate Program in the Biomedical Sciences Admissions Interviewer (1999, 2000, 2012)

School of Medicine Strategic Planning (1995) Mission and Vision Task Force Core Competencies Task Force Programs of Excellence Committee Research Committee of the Medical Faculty (1995-1998) Productivity Planning Advisory Research Task Force (1997) Ruth T. Bohan Teaching Award Committee (1997) Associate Dean for Cultural Enhancement and Diversity Search Committee (1998-1999) Family Medicine Chair Search Committee (1998-2001) Research Space Committee (1999-2003)

Academic Committee (2002-2008, 2009-2013), Vice-Chair (2003-2004), Chair (2004-2005) Student Promotions and Special Programs Subcommittee of the Academic Committee (2002-2008, 2009-

2013), Vice-Chair (2011-2012), Chair (2005-2007, 2012-2013) Faculty Council (2002-2005, 2010-2012, 2014-present), Member-At-Large (2002-2004, 2014-present),

Vice-Chair-elect (2010-2011), Vice-Chair (2011-2012) Executive Committee of the Faculty Council (2002-2005; 2010-2012, 2014-present) Admissions Interviewer (2003-present) LCME Self-study - Educational Program: Curriculum Design & Content Committee (2004-2005) Biomedical Research Training Program Selection Committee (2005, 2008) Task Force for the Evaluation of Chair Review (2006-2007) Mass Spectrometry Core Advisory Committee (2007-2010) Professional Development and Faculty Affairs Planning Committee (2008) Responsible Conduct of Research Planning Committee (2008-2010) Faculty Dismissal Appeal Committee (2009) Orr Academic Society, Faculty Advisor (2011-present) Phase I Curriculum Oversight Subcommittee (2011-present) Course Review Committee – CORE 830 (2012-2013) Education Council (2012-2014) (At-large member, Dean-appointed) Appointments, Promotion & Tenure Committee (2012-present) LCME Educational Resources Self-study Group (2012-2013) Surgery Chair Search Committee (2013-2014) Phase I Content Committee (2013-present)

Kansas Intellectual and Developmental Disabilities Retardation Research Center

Rodent Behavior Core Advisory Committee (2004-present) Research Design and Analysis Core Advisory Committee (2005-2009) Neuroscience Faculty Search Committee (2005-2006) Resource Advisory Committee (2009-present) Space Committee (2010-present)

Medical Center Institutional Animal Care and Use Committee (1996-1998, 2012-2013)

Faculty Assembly Resources and Facilities Planning Committee (2002-2005) Faculty Assembly Faculty Concerns Committee (2007-2010), Chair (2008-2009) Faculty Assembly (2008-2009) Faculty Assembly Steering Committee (2008-2009) Faculty Assembly Elections Committee (2015-present) Vendor Relations Committee (2009-present)


EVC Transition Team: KUMC Leadership and Faculty Development (2012) Women in Medicine and Science (WIMS) Mentoring Committee (2010-present) Women in Medicine and Science (WIMS) WIMS Delegates (2010-present) Women in Medicine and Science (WIMS) Executive Committee, School of Medicine Basic Science

Representative (2012-2013, 2014-present) External Professional Activities and Service: Local Organizations: Blue Valley High School Mentorship Academy Program, Mentor 1994-1995. Sigma Xi, Chapter #260, President-elect, 1999-2000; President, 2000-2001. Society for Neuroscience Kansas City Chapter, Brain Awareness Fair Keynote Speaker, 2011-2014. Executive

Committee member, 2011-present, Treasurer, 2014-present Medical Reserve Corp of Kansas City, Member (2009-present); Training Committee, 2011-present Kansas City University of Medicine and Biosciences, Judge (2013) Annual Research Symposium.

National Organizations: ASPET Committee on Women in Pharmacology, 2001-2006, Acting Chair, 2005. Symposia Organized: The Kansas IDeA Symposium and Worksession – “Nitric Oxide and the Nervous System” - May 24-25, 1996. INABIS ‘98: 5th Internet Congress on Biomedical Sciences Symposium – “Monoamine Oxidase Inhibitors:

Multiple Effects and Sites of Action” - December 6-17, 1998. Sigma Xi Annual Banquet – “Update on the Stowers Institute: Research at the Institute and its Impact on the

Region” - April 26, 2000. Sigma Xi Seminar Series - October, 2000 - April, 2001.

Symposia Sessions Chaired: Symposium Chair: The Kansas IDeA Symposium and Worksession – “Nitric Oxide and the Nervous System” -

May 24-25, 1996. Worksession Chair: The Kansas IDeA Symposium and Worksession – “Nitric Oxide and the Nervous System” -

May 24-25, 1996. Worksession Chair: The Kansas IDeA Symposium and Worksession – “Oxidative Regulation of Gene

Expression: Role in Neurodegenerative Diseases” - October 11-12, 1996. Symposium Chair: INABIS ‘98: 5th Internet Congress on Biomedical Sciences Symposium – “Monoamine

Oxidase Inhibitors: Multiple Effects and Sites of Action” - December 6-17, 1998. Symposium Chair: American Oil Chemists: PUFA in Maternal and Child Health Plenary Session – “PUFA and

Cerebral Function: Focus on Monoaminergic Neurotransmitters” - September 10-13, 2000. Symposium Chair: American Oil Chemists: Maternal and Infant LCPUFA Workshop – “Focus on Infant

Development: Plausible and New Outcomes” – May 3-4, 2003. Symposium Chair: International Society for the Study of Fatty Acids and Lipids – “Brain Composition and

Function I” – July 23-28, 2006. Symposium Chair: International Society for the Study of Fatty Acids and Lipids – “Neuropsychology I” – May

17-22, 2008.


Consultant: University of British Columbia, Workshop on Pharmacogenetics, 1999 Chemical Signatures Technologies, Inc., 1999 Aventis Pharmaceuticals, 2001. Law Offices of Stephanie Warmund, 2005-2006 Rasmussen, Willis, Dickey, & Moore, L.L.C., 2006 Medical DecisionPoint, 2008 Case & Roberts, P.C., 2013 Shook, Hardy & Bacon, L.L.P., 2014

Grant Review: Chartered Member – NIH Developmental Brain Disorders (DBD) Study Section, 2005-2009.

Ad-hoc - Life Span Institute, University of Kansas – 1996, 2007 University of Kansas Alzheimer’s Disease Center - 2012 Department of Veterans Affairs – 1997 Rehabilitation R&D 3/10 National Science Foundation - 1998 The Ontario Mental Health Foundation - 2001 University of Missouri Research Board - 2002 Parkinson’s Disease Society of the United Kingdom – 2008, 2010, 2011 University of Kansas Medical Center Frontiers, Clinical, and Lied Pilot Grants – 2013-2014 American Institute of Biological Sciences - 2014 National Institute of Health – 6/97 ZMH1-B(02) - 2/98

DBD - 11/04, 6/05, 10/12, 10/14 ZDA1 GXM-A (19) - 12/06 NIDA-L - 3/08 ZRG1 BDCN-M (95) - 6/09 ZMH1 ERB-S (02) S – 2/11 DDNS – 6/14 ZRG1 MDCN-C (58) – 6/14 ZRG1 BDCN-R (02) M – 7/14


Editorial and Manuscript Review: Editorial Advisory Board - Life Sciences, 2003-present Ad-hoc Manuscript Review:

ACS Chemical Neuroscience Advances in Pharmacology Aging Research Reviews Behavioral Brain Research Biochemica et Biophysica Acta Biochemical Pharmacology Biological Psychiatry BioMed Central Psychiatry BioMed Research International BioTechniques Brain Research British Journal of Nutrition Clinical Lipidology CNS & Neurological Disorders – Drug Targets Current Drug Targets - CNS and Neurological

Disorders Current Neuropharmacology Drug Metabolism & Toxicology European Journal of Lipid Science and Technology European Journal of Neuroscience Expert Review of Obstetrics and Gynecology Journal of Affective Disorders Journal of Biomedicine and Biotechnology Journal of Drug Metabolism and Toxicology Journal of Experimental Pharmacology Journal of Lipid Research Journal of Medicinal Chemistry Journal of Neurochemistry Journal of Neuroendocrinology Journal of Neuroscience Journal of Neuroscience Methods Journal of Nutrition

Journal of Nutritional Biochemistry Journal of Parenteral and Enteral Nutrition Journal of Pharmacology and Experimental

Therapeutics Journal of Psychopharmacology International Journal of Neuropsychopharmacology Life Sciences Lipids Liver International Medical Science Monitor Neurochemistry International Neuropharmacology Neuropsychopharmacology Neuroscience Neuroscience Letters Neurotoxicology and Teratology Nutrients Nutrition and Metabolism Pediatric Research Pharmacology, Biochemistry, and Behavior Physiology & Behavior PLoS One Proceedings of the National Academy of Science Progress in Neuro-psychopharmacology &

Biological Psychiatry Psychiatry and Clinical Neurosciences Psychiatry Research Psychoneuroendocrinology Psychopharmacology Regulatory Toxicology & Pharmacology Synapse

Professional Affiliations:

American Association of University Professors (2003 – present) American College of Neuropsychopharmacology - Associate member (1998-2002) American Society for Pharmacology and Experimental Therapeutics (1994 – present) International Association of Medical Science Educations (2015 – present) International Society for the Study of Fatty Acids and Lipids (2006 – present) Sigma Xi (1999-2010) Society for Neuroscience (1987 – present) Society for Neuroscience: Kansas City Chapter (1993 – present)


Honors and Awards: Undergraduate:

Miller Scholarship. University of California, Davis, CA, 1981-1982. William W. Stout Scholarship. University of California, Davis, CA, 1981-1982. Dean’s List. University of California, Davis, CA, 1981-1984. President's Undergraduate Fellowship. University of California, Davis, CA, 1984.

Graduate: NIH Predoctoral Training Fellowship in Pharmacology. Duke University, Durham, NC, 1985-1988. Conference Travel Fellowships. Duke University, Durham, NC, 1987-1989. Roche Laboratories Award for Excellence in Basic Research, Graduate Student Division, Second Place.

National Student Research Forum, Galveston, TX, 1989. University of Texas Medical Branch Psychiatry and Behavioral Sciences Award. National Student

Research Forum, Galveston, TX, 1989. Omnitech Travel Award. Omnitech Electronics, Inc., Columbus, OH, 1989.

Postgraduate: Pharmacology Research Associate (PRAT) Fellowship. National Institute of General Medical Sciences, 1989 (not activated). Young Investigator Award. International Congress on Schizophrenia Research, Tuscon, AZ, 1991. Commitment to Excellence Award. The DuPont Merck Pharmaceutical Company, Wilmington, DE, 1993. Young Scientist Travel Award. American Society for Pharmacology and Experimental Therapeutics, XIIth

IUPHAR Congress, Montreal, Canada, 1994. American College of Neuropsychopharmacology/Mead Johnson Travel Award. 1994. Faculty Travel Scholarships. University of Kansas Medical Center, Kansas City, KS, 1994, 1998, 1999,

2001, 2002, 2010. Kansas IDeA Network for Research Excellence (K-INBRE) Faculty Scholar Award. University of Kansas

Medical Center, Kansas City, KS 2006. KansasBio K-INBRE Symposium Outstanding Achievement Award. K-INBRE Symposium. 2008. Women in Medicine and Science Scholarship to attend the AAMC Mid-Career Faculty Professional

Development Seminar, University of Kansas Medical Center, Kansas City, KS, 2008. Chancellor’s Distinguished Teaching Award. University of Kansas, Kansas City, KS, 2012. Marjorie S. Sirridge, MD Excellence in Medicine and Science Award. University of Kansas School of

Medicine Women in Medicine and Science, Kansas City, KS, 2012. Academy of Medical Educators Travel Award to attend the International Association of Medical Science

Educators Meeting, University of Kansas Medical Center, Kansas City, KS, 2015.


Peer-reviewed Research Reports:

1. Slotkin TA, Levant B, Orband-Miller L, Queen KL, Stasheff S (1988) Do sympathetic neurons coordinate cellular development in the heart and kidney? Effects of neonatal central and peripheral catecholaminergic lesions on cardiac and renal nucleic acids and proteins. J. Pharmacol. Exp. Ther., 244:166-172. PMID: 2447274

2. Levant B, Bissette G, Nemeroff CB (1989) Effects of anticholinergic drugs on regional brain neurotensin concentrations. Eur. J. Pharmacol., 165:327-330. PMID: 2776835

3. Levant B, Nemeroff CB (1990) Sigma receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. J. Pharmacol. Exp. Ther., 254:330-335. PMID: 1973198

4. Nemeroff CB, Bissette G, Levant B, Kilts CD, Campbell A, Baldessarini RJ (1991) Effects of the isomers of N-n-propylnorapomorphine and haloperidol on regional concentrations of neurotensin in rat brain. Neuropsychopharmacology, 4:27-33. PMID: 1672249

5. Levant B, Bissette G, Widerlöv E, Nemeroff CB (1991) Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs. Regul. Peptides., 32:193-202. PMID: 1674615

6. Levant B, Bissette G, Davis MD, Heffner TG, Nemeroff CB (1991) Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations. Synapse, 9:225-230. PMID: 1685600

7. Levant B, Merchant KM, Dorsa DM, Nemeroff CB (1992) BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum. Mol. Brain. Res., 12:279-284. PMID: 1349718

8. Levant B, Nemeroff CB (1992) Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: focus on haloperidol and BMY 14802. J. Pharmacol. Exp. Ther., 262:348-355. PMID: 1625208

9. Myers B, Levant B, Bissette G, Nemeroff CB (1992) Pharmacological specificity of the increases in neurotensin concentrations after antipsychotic drug treatment. Brain Res., 575:325-328. PMID: 1349254

10. Levant B, Grigoriadis DE, De Souza EB (1992) Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. J. Pharmacol. Exp. Ther., 262:929-935. PMID: 1356154

11. Levant B, Grigoriadis DE, De Souza EB (1993) [3H]Quinpirole binding to putative D2 and D3 dopamine receptors in rat brain and pituitary gland: A quantitative autoradiographic study. J. Pharmacol. Exp. Ther., 264:991-1001. PMID: 8437136

12. Levant B, De Souza EB (1993) Differential pharmacological profile of striatal and cerebellar dopamine receptors: Identification of a discrete population of putative D3 receptors. Synapse, 14:90-95. PMID: 8099762

13. Levant B, Grigoriadis DE, De Souza EB (1993) Monoamine oxidase inhibitors inhibit [3H]quinpirole binding in rat striatal membranes. Eur. J. Pharmacol.-Mol. Pharmacol., 246:171-178. PMID: 8104153

14. Levant B, Grigoriadis DE, De Souza EB (1995) Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. Eur. J. Pharmacol., 278:243-247. PMID: 7589161

15. Levant B (1995) Differential sensitivity of [3H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Brain Res., 698:146-154. PMID: 8581473

16. Bissette G, Griff D, Carnes M, Lavine M, Levant B (1995) Apparent seasonal rhythms in hypothalamic neuropeptides in rats without photoperiod changes. Endocrinology, 136:622-628. PMID: 7835296

17. Levant B, Bancroft GN, Selkirk CM (1996) In vivo occupancy of D2 dopamine receptors by 7-OH-DPAT. Synapse, 24:60-64. PMID: 9046077


18. Levant B, Moehlenkamp JD, Morgan KA, Leonard NL, Cheng CC (1996) Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: Evidence for a potential novel binding site. J. Pharmacol. Exp. Ther., 278:145-153. PMID: 8764345

19. Levant B, Vansell NR (1997) In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsycho-pharmacology, 17:67-71. PMID: 9252981

20. Bancroft GN, Morgan KA, Flietstra RJ, Levant B (1998) Binding of [3H]PD 128907, a putatively selective ligand for the D3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology, 18:305-316. PMID: 9509498

21. Flietstra RJ, Levant B (1998) Comparison of D2/D3 dopamine receptor affinity of dopaminergic compounds in rat brain. Life Sci,. 62:1825-1831.

22. Levant B (1998) Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res., 800:269-274. PMID: 9685676

23. Levant B, Bancroft GN (1998) Inhibition of [3H]quinpirole binding by a monoamine oxidase inhibitor in subcellular fractions of rat striatum. Life Sci., 63:1643-1651. PMID: 9806217

24. Levant B, Cross RA, Pazdernik TL (1998) Alterations in local cerebral glucose utilization induced by D3 dopamine receptor-selective doses of 7-OH-DPAT and nafadotride. Brain Res,. 812:193-199. PMID: 9813322

25. Levant B, Garimelli B, Shafer RA, Merchant KM (1999) Increased levels of proneurotensin/neuromedin N mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride. Neuropsycho-pharmacology, 21:304-311. PMID: 10432478

26. Gilliland SL, Alper RH, Levant B (2000) Pharmacology of quinpirole-stimulated [35S]GTPγS binding: discrepancy with receptor binding profile. Eur. J. Pharmacol., 392:125-128. PMID: 10762663

27. Levant B, McCarson KE (2001) D3 dopamine receptors in rat spinal cord: implications for sensory and motor function. Neurosci. Lett., 303:9-12. PMID: 11297811

28. Levant B, Morgan KA, Ahlgren-Beckendorf JA, Grandy DK, Chen K, Shih JE, Seif I (2001) Modulation of [3H]quinpirole binding at striatal D2 dopamine receptors by a monoamine oxidaseA-like site: evidence from radioligand binding studies and D2 receptor- and MAOA-deficient mice. Life Sci., 70:229-241. PMID: 11787947

29. Carpenter TL, Pazdernik TL, Levant B (2003) Differences in quinpirole-induced local cerebral glucose utilization between naïve and quinpirole-sensitized rats. Brain Res., 964:295-301. PMID: 12576190

30. Richtand NM, Welge JA, Levant B, Logue AD, Hayes S, Pritchard L, Geracioti TD, Coolen L, Berger SP (2003) Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration. Neuropsychopharmacology, 28:1422-1432. PMID: 12700693

31. Varady J, Wu X, Fang X, Min J, Hu Z, Levant B, Wang S (2003) Modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor and discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J. Med. Chem., 46:4377-4392. PMID: 14521403

32. Levant B, Radel JD, Carlson SE (2004) Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation. Behav. Brain Res., 152:49-57. PMID: 15135968. Selected by Faculty of 1000 Biology; F1000 factor 3.0; http://www.f1000biology.com/article/id/1025539/evaluation

33. Witkin JM, Dijkstra D, Levant B, Akunne HC, Zapata A, Kaminski R, Peters S, Shannon HE, Gasior M (2004) Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907]. J. Pharmacol. Exp. Ther., 308:957-964. PMID: 14711932


34. Levant B, Pazdernik TL (2004) Differential effects of ibogaine on local cerebral glucose utilization in drug-naïve and morphine-dependent rats. Brain Res., 1003:159-167. PMID: 15019575

35. Wu X, Chen J, Ji M, Varady J, Levant B, Wang S (2004) Design, synthesis and evaluation of hexahydribenz[f]-isoquinolines as a novel class of dopamine 3 receptor ligands. Bioorg. Med. Chem. Lett., 14:5813-5816. PMID: 15501046

36. Richards TL, Pazdernik TL, Levant B (2005) Altered quinpirole-induced local cerebral glucose utilization in anterior cortical regions in rats after sensitization to quinpirole. Brain Res., 1042:53-61. PMID: 15823253

37. Ji M, Chen J, Wu J, Varady J, Levant B, Wang S (2005) Design, synthesis, and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of dopamine receptor 3 (D3) ligands. Bioorg. Med. Chem. Lett., 15:1701-1705. PMID: 15745825

38. Ding K, Chen J, Ji M, Wu X, Varady J, Levant B, Wang S (2005) Enantiomerically pure hexahydro-pyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands. J. Med. Chem., 48:3171-3181. PMID: 15745825

39. Chen J, Ding K, Levant B, Wang S (2006) Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility. Bioorg. Med. Chem. Lett., 16:443-446. PMID: 16290142

40. Levant B, Crane JF, Carlson SE (2006) Sub-chronic treatment with antipsychotic drugs does not alter brain phospholipid fatty acid composition in rats. Prog. Neuro-psychopharmacol Biol. Psychiatr., 30:728-732. PMID: 16442197

41. Levant B, Radel JD, Carlson SE (2006) Reduced brain DHA content after a single reproductive cycle in female rats fed a diet deficient in n-3 polyunsaturated fatty acids. Biol. Psychiatry, 60:987-990. PMID: 16499882

42. McNamara RK, Levant B, Taylor B, Ahlbrand R, Lu Y, Sullivan JR, Stanford K, Richtand NM (2006) C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated inhibitor function relative to DBA/2J mice. Neuroscience, 143:141-153. PMID: 16938406. PMCID: PMC1815378

43. Levant B, Ozias MK, Carlson SE (2006) Diet (n-3) polyunsaturated fatty acid content and parity interact to alter maternal rat brain phospholipid fatty acid composition. J. Nutr., 136:2236-2242. PMID: 16857847

44. Levant B, Ozias MK, Jones KA, Carlson SE (2006) Differential effects of modulation of docosahexaenoic acid content during development in specific regions of rat brain. Lipids, 41:407-414. PMID: 16933785

45. Levant B, Ozias MK, Carlson SE (2006) Sex-specific effects of variation in brain long-chain polyunsat-urated fatty acid composition on locomotor activity in the developing rat. Physiol. Behav., 89:196-204. PMID: 16875705

46. Ozias MK, Carlson SE, Levant B (2007) Maternal parity and diet (n-3) polyunsaturated fatty acid content influence brain phospholipid fatty acid docosahexaenoic acid accretion in the developing rat. J. Nutr., 137:125-129. PMID: 17182812

47. Levant B, Ozias MK, Carlson SE (2007) Specific brain regions of the female rat are differentially depleted of docosahexaenoic acid by reproductive activity and an (n-3) fatty acid-deficient diet. J. Nutr., 137:130-134. PMID: 17182813

48. Pierce JD, Jagathesan J, Levant, B, Winter M, McCarson KE, Clancy RD (2007) Detection of dopamine receptor subtypes in the rat diaphragm. Heart Lung, 36:58-63. PMID: 17234478

49. Richards TL, Pazdernik TL, Levant B (2007) Clorgyline-induced modification of behavioral sensitization to quinpirole: effects on local cerebral glucose utilization. Brain Res., 1160:124-133. PMID: 17573047. PMCID: PMC2099299


50. Levant B, Ozias MK, Carlson SE (2007) Diet (n-3) polyunsaturated fatty acid content and parity affect liver and erythrocyte phospholipid fatty acid composition of the female rat. J. Nutr., 137:2425-2430. PMID: 17951480

51. Richards TL, Pazdernik TL, Levant B (2007) Basal local cerebral glucose utilization is not altered by behavioral sensitization to quinpirole. Neurosci. Lett., 429:165-168. PMID: 17997222. PMCID: PMC2171330

52. Ahmad SO, Park J, Radel JD, Levant B (2008) Reduced numbers of dopamine neurons in the substantia nigra pars compacta and ventral tegmental area of rats fed an n-3 polyunsaturated fatty acid-deficient diet: a stereological study. Neurosci. Lett., 438:303-307. PMID: 18499349. PMCID: PMC2493469

53. Levant B, Ozias MK, Davis PF, Winter M, Russell KL, Carlson SE, Reed GA, McCarson KE (2008) Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. Psychoneuroendocrinology, 33:1279-1292. PMID: 18707812. PMCID: PMC2582014

54. Witkin JM, Gasior M, Kaminski R, Levant B (2008) The dopamineD3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD-128,907] protects against acute and cocaine kindled seizures in mice: further evidence for the involvement of D3 receptors. J. Pharmacol. Exp. Ther., 326:930-938. PMID: 18566292.

55. Culver KE, Szechtman H, Levant B (2008) Altered dopamine D2-like receptor binding in rats with behavioral sensitization to quinpirole: effects of pre-treatment with Ro 41-1049. Eur. J. Pharmacol., 592:67-72. PMID: 18644362. PMCID: PMC2577911

56. Chen J, Collins GT, Zhang J, Yang C-Y, Levant B, Woods J, Wang S (2008) Design, synthesis and evaluation of potent and selective dopamine 3 receptor ligands with a novel profile of pharmacologic and behavioral activity. J. Med. Chem., 51:5905-5908. PMID: 18785726. PMCID: PMC2662387

57. Davis PF, Ozias MK, Carlson SE, Reed GE, Winter MK, McCarson KE, Levant B (2010) Dopamine receptor alterations in female rats with diet-induced decreased brain docosahexaenoic acid (DHA): interactions with reproductive status. Nutr. Neurosci., 13:161-169. PMID: 20670471 PMCID: PMC2955509

58. Fowler SC, Zarcone TJ, Levant B (2010) Methylphenidate attenuates rats’ preference for a novel spatial stimulus introduced into a familiar environment: Assessment using a force-plate actometer. J. Neurosci. Meth., 189:36-43. PMID: 20346982. PMCID: PMC2864804

59. Oien DB, Ortiz AN, Rittel AG, Dobrowksy RT, Johnson MA, Levant B, Fowler SC, Moskovitz J (2010) Dopamine D2 receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse. J. Neurochem., 114:51-61. PMID: 20374422. PMCID: PMC2933736

60. Levant B, Zarcone TJ, Fowler SC (2010) Developmental effects of dietary n-3 fatty acid content on activity and response to spatial novelty. Physiol. Behav., 101:176-183. PMID: 20457171. PMCID: PMC2923479

61. Levant B, Zarcone TJ, Davis PF, Ozias MK, Fowler SC (2011) Differences in methylphenidate dose-response between peri-adolescent and adult rats in the familiar arena – novel alcove task. J. Pharmacol. Exp. Ther., 337:87-91. PMID: 21205916. PMCID: PMC3063734

62. Raveendran VV, Tan X, Sweeney ME, Levant B, Slusser J, Stechschulte DJ, Dileepan KN (2011) Lipopolysaccharide induces H1 receptor expression and enhances histamine responsiveness in human coronary artery endothelial cells. J. Immunol., 132:578-588. PMID: 21255012. PMCID: PMC3075511

63. Collins GE, Truong YN, Levant B, Chen J, Wang S, Woods JH (2011) Behavioral sensitization to cocaine in rats: Evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. Psychopharma-cology, 215:609-620. PMID: 21207013. PMCID: PMC3102773


64. Russell KL, Kutchko KM, Fowler SC, Berman NEJ, Levant B (2011) Sensorimotor behavioral tests for use in a juvenile rat model of traumatic brain injury: assessment of sex differences. J. Neurosci. Meth. 199:214-222. PMID: 21600923. PMCID: PMC3142868

65. Chen J, Collins GT, Levant B, Woods JH, Deschamps JR, Wang S (2011) CJ-1639: A potent and highly selective dopamine D3 receptor full agonist. ACS Med. Chem. Lett. 2:620-625. PMID: 2215662. PMCID: PMC3224040

66. Chen J, Levant B, Wang S (2012) High-affinity and selective dopamine D3 full agonists. (2012) Bioorg. Med. Chem. Lett. 22:5612-5617. PMID: 22871578. PMCID: PMC3461280

67. Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B (2012) A novel use of combined tyrosine hydroxylase and silver nucleolar staining to determine the effects of a unilateral intrastriatal 6-hydroxydopamine lesion in the substantia nigra: a stereological study. J. Neurosci. Meth. 210:187-194. PMID: 22850559. PMCID: PMC3443281

68. Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B (2013) Altered nucleolar morphology in substantia nigra following 6-hydroxydopamine lesion in rats. Neurosci. Lett. 546:26-30. PMID: 23643997. PMCID: PMC3679339

69. Russell KL, Berman NEJ, Levant B (2013) Low brain DHA content worsens sensorimotor outcomes after TBI and decreases TBI-induced Timp-1 expression in juvenile rats. Prostaglandins Leukot. Essent. Fatty Acids 89:97-015 PMID: 23796971. PMCID: PMC3753049

70. Levant B, Ozias MK, Guilford BL, Wright DE (2013) Streptozotocin-induced diabetes partially attenuates the effects of a high-fat diet on liver and brain fatty acid composition in mice. Lipids 48:939-948. PMID: 2383338. PMCID: PMC376037

71. Russell KL, Berman NEB, Gregg PRA, Levant B (2014) Fish oil improves motor function, limits blood-brain barrier disruption, and reduces MMP9 gene expression in a rat model of juvenile traumatic brain injury. Prostaglandins Leukot. Essent. Fatty Acids 90:5-11. PMID: 24342130. PMCID: PMC3906920

72. Chen J, Levant B, Cheng J, Keck TM, Newman AH, Wang S (2014) Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D3 receptor antagonists. J. Med. Chem. 57:4962-4968. PMID: 24848155. PMCID: PMC4216217

73. Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B (2014) Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat. Brain Res. 1574:113-119. PMID: 2494804. PMCID: PMC4115364

74. Chen J, Cheng J, Levant B, Li X, Zhao T, Wen B, Luo R, Sun D, Wang S (2014) Pramipexole derivatives as potent and selective dopamine D3 receptor agonists with improved human microsomal stability. Chem. Med. Chem. 9:2653-2660. PMID: 25338762. PMCID: PMC4277207

Reviews and Book Chapters:

1. Levant B, Nemeroff CB (1988) The psychobiology of neurotensin. In: The Neurobiology of Mood. Current Topics in Neuroendocrinology, Volume 8, (D Ganten and D Pfaff, Eds.). Springer-Verlag, Inc., Berlin, pp. 231-262. (Invited)

2. Levant B, Bissette G, Nemeroff CB (1988) Further evidence for neurotensin-dopamine interactions in the central nervous system. In: Pharmacology and Functional Regulation of Dopaminergic Neurons (PM Beart, GN Woodruff, and DM Jackson, Eds.). McMillan Press, LTD, London, pp. 247-265. (Invited)

3. Levant B, Bissette G, Nemeroff CB (1991) Neurotensin. In: Neuropeptides and Psychiatric Disorders (CB Nemeroff, Ed.). APA Press, Washington, D.C., pp. 149-168. (Invited)

http://dx.doi.org/10.1016/j.plefa.2013.11.003


4. Bissette G, Levant B, Nemeroff CB (1991) Neurotensin and its possible significance in the pathogenesis of schizophrenia. In: Volume Transmission in the Brain (K Fuxe and L Agnati, Eds.). Raven Press, New York, pp. 549-556. (Invited)

5. Nemeroff CB, Levant B, Myers B, Bissette G (1992) Neurotensin, antipsychotic drugs and schizophrenia: basic and clinical studies. Ann. N.Y. Acad. Sci., 668:146-156. PMID: 1361110 (Invited)

6. Levant B (1996) Distribution of dopamine receptor subtypes in CNS. In: Dopamine. CNS Neurotransmitters and Neuromodulators, Volume 3 (TW Stone, Ed.). CRC Press, Boca Raton, FL, pp. 77-88. (Invited)

7. Enna SJ, Gordon MA, Levant B (1996) Central nervous system drugs. In: Mosby’s Ace the Boards: Pharmacology (SJ Enna, MA Gordon and TL Pazdernik, Eds.). Mosby, St. Louis, pp. 184-230. (Invited)

8. Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev., 49:231-252. PMID: 9311022 (Peer-reviewed)

9. Levant B (1998) Characterization of dopamine receptors. In: Current Protocols in Pharmacology (J Ferkany and SJ Enna, Eds). John Wiley & Sons, New York, pp. 1.6.1-1.6.16. (Invited)

10. Shafer RA, Levant B (1998) The D3 dopamine receptor in cellular and organismal function. Psychopharmacology, 135:1-16. PMID: 9489928 (Invited and peer-reviewed)

11. Levant B, Ling ZD, Carvey PM (1999) Dopamine D3 receptor: relevance for the drug treatment of Parkinson’s disease. CNS Drugs, 12:391-402. (Invited and peer-reviewed)

12. Levant B, Gilliland SL, Culver KE, Szechtman H (2000) Novel drug interactions at CNS dopamine receptors. Potential role in psychopathology and toxicity. In: Molecular Drug Metabolism and Toxicity. (G Williams, OI Aruoma, Eds). OICA International, St. Lucia, pp. 201-216. (Invited and peer-reviewed)

13. Levant B (2002) Novel drug interactions at D2 dopamine receptors: modulation of [3H]quinpirole binding by monoamine oxidase inhibitors. Life Sci., 71:2691-2700. PMID: 12383877 (Invited and peer-reviewed)

14. Levant B (2003) Dopamine receptor binding and quantitative autoradiographic study. Meth. Mol. Med., 79:297-313. PMID: 12506705 (Invited and peer-reviewed)

15. Ahlgren-Beckendorf JA, Levant B (2004) Signaling mechanisms of the D3 dopamine receptor. J. Recept. Sig. Trans., 24:117-130. PMID: 15521358 (Invited and peer-reviewed)

16. Levant B (2007) Characterization of dopamine receptors. In: Current Protocols in Pharmacology (J Ferkany and SJ Enna, Eds). John Wiley & Sons, New York, pp. 1.6.1-1.6.16. (Invited)

17. Levant B, Cheatham CL (2007) Functionele rol van LCP bij hersenontwikkeling [Functional role of LCP in brain development]. F.A.J. Muskiet (Ed.). Special Vetzuren, Wetenschappelijke pulicatie over kindervoeding. Groningen, Netherlands: Elsevier Gezondheidszorg. pp. 12-14. (Invited)

18. Levant B (2010) Brain n-3 (omega-3) fatty acids in neurochemistry, behavior, and mood: implications for the treatment and prevention of non-puerperal and postpartum depression. In: Lipids: Categories, Biological Functions and Metabolism, Nutrition, and Health (PL Gilmore, Ed). Nova Science, Hauppauge, NY. pp.127-152. (Invited and peer-reviewed)

19. Levant B (2011) N-3 (Omega-3) fatty acids in postpartum depression: implications for prevention and treatment. Depress. Res. Treat., 2011: 467349. 16 pages. doi:10.1155/2011/467349. Available on-line: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989696/pdf/DRT2011-467349.pdf (Accessed 9/21/11). PMID: 21151517. PMCID: PMC2989696 (Invited and peer-reviewed)

20. Levant B (2013) N-3 (Omega-3) polyunsaturated fatty acids in the pathophysiology and treatment of depression: pre-clinical evidence. CNS Neurol. Disord. Drug Targets, 12:450-459. PMID: 23574159. PMCID: PMC4115447 (Invited and peer-reviewed)

21. Levant B (2014) Schizophrenia. Reference Module in Biomedical Sciences, 2014. Elsevier. 21-Oct-2014 doi: 10.1016/B978-0-12-801238-3.05291-0. (Invited)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989696/pdf/DRT2011-467349.pdf


23. Levant B (2014) Obsessive Compulsive Disorder. Reference Module in Biomedical Sciences, 2014. Elsevier. 21-Oct-2014 doi: 10.1016/B978-0-12-801238-3.05186-2. (Invited)

24. Levant B (2014) Attention Deficit Hyperactivity Disorder. Reference Module in Biomedical Sciences, 2014. Elsevier. 21-Oct-2014 doi: 10.1016/B978-0-12-801238-3.04862-5. (Invited)

25. Levant B (2014) Post Traumatic Stress Disorder. Reference Module in Biomedical Sciences, 2014. Elsevier. 21-Oct-2014 doi: 10.1016/B978-0-12-801238-3.05240-5. (Invited)

26. Levant B (2014) Bipolar Disorder. Reference Module in Biomedical Sciences, 2014. Elsevier. 21-Oct-2014 doi: 10.1016/B978-0-12-801238-3.05132-1. (Invited)

27. Levant B (2014) Anxiety Disorders. Reference Module in Biomedical Sciences, 2014. Elsevier. 21-Oct-2014 doi: 10.1016/B978-0-12-801238-3.04854-6. (Invited)

28. Levant B, Parkinson JA (2014) Positive emotions and reward: Appetitive systems – Amygdala and striatum. Reference Module in Biomedical Sciences, 2014. Elsevier. 21-Oct-2014 doi: 10.1016/B978-0-12-801238-3.04498-6 (Accessed 6/22/15). (Invited)

29. Levant B (2015) Emotional States. Reference Module in Biomedical Sciences, 2015. Elsevier. 06-Mar-2015 doi: 10.1016/B978-0-12-801238-3.04998-9. (Invited)

30. Levant B (2015) Role of n-3 (omega-3) polyunsaturated fatty acids in postpartum depression: mechanisms and implications for prevention and treatment. In: Omega-3 Fatty Acids: Keys to Nutritional Health (MV Hedge, AA Zanwar, SP Adekar, Eds). Speinger Science + Business Media (in press). (Invited)

Book Reviews:

1. Levant B (2003) Review of Pharmacology for Anaesthesia and Intensive Care, 2nd Edition. Doody's Review Service (on-line). Available: http://www.doody.com. (Accessed 11/25/03).

2. Levant B (2005) Review of Drug Discovery for Nervous System Diseases, Doody's Review Service (on-line). Available: http://www.doody.com. (Accessed 1/31/05).

3. Levant B (2005) Review of Applying Genomic and Proteomic Microarray Technology in Drug Discovery, Doody's Review Service (on-line). Available: http://www.doody.com. (Accessed 5/27/05).

4. Levant B (2009) Review of Functional Selectivity of G Protein-coupled Receptor Ligands, Doody's Review Service (on-line). Available: http://www.doody.com. (Accessed 8/7/09).

5. Levant B (2011) Review of The Blood-Brain Barrier and Other Neural Barriers: Reviews and Protocols, Doody's Review Service (on-line). Available: http://www.doody.com.

6. Levant B (2013) Review of Dopamine: Methods and Protocols, Doody's Review Service (on-line). Available: http://www.doody.com.

Abstracts:

1. Levant B, Bissette G, Parker Y-M, Nemeroff CB (1987) Alterations in neurotensin- and bombesin-like immunoreactivity in MPTP-treated mice. North Carolina Society for Neuroscience, 53.

2. Levant B, Bissette G, Parker Y-M, Nemeroff CB (1987) Alterations in regional neuropeptide concentration in MPTP-treated mice. Soc. Neurosci. Abst., 13:567.

3. Levant B, Bissette G, Parker Y-M, Nemeroff CB (1988) Alterations in neurotensin- and bombesin-like immunoreactivity in MPTP-treated mice. Ann. N.Y. Acad. Sci., 537:515-517.

http://www.sciencedirect.com/%20science/article/pii/%20B9780128012383044986

http://www.sciencedirect.com/%20science/article/pii/%20B9780128012383044986


4. Levant B, Bissette G, Nemeroff CB (1988) Anticholinergic drugs do not alter neurotensin concentrations in the nucleus accumbens or caudate. Soc. Neurosci. Abst., 14:114.

5. Levant B, Bissette G, Nemeroff CB (1989) Sigma receptors may mediate antipsychotic drug-induced increases in regional brain neurotensin concentrations. National Student Research Forum, 6.

6. Levant B, Bissette G, Nemeroff CB (1989) Sigma antagonist MJ 14802 increases neurotensin concentration in the rat nucleus accumbens and caudate nucleus. Soc. Neurosci. Abst., 15:811.

7. Nemeroff CB, Kilts CD, Levant B, Campbell A, Bissette G, Neumeyer JL, Baldessarini RJ (1989) Effects of aporphines on regional brain neurotensin concentrations: implications for development of novel antipsychotic drugs. Soc. Neurosci. Abst., 15:1122:

8. Nemeroff CB, Levant B, Bissette G (1989) Peptidergic modulation of midbrain dopamine neurons: focus on neurotensin. Proc. 28th Ann. Mtg. Am. Coll. Neuropsychopharmacol., 22.

9. Levant B, Nemeroff CB (1990) Effects of sigma receptor blockade on regional brain neurotensin concentrations. Eur. J. Pharmacol., 183:2323-2324.

10. Levant B, Nemeroff CB (1990) Effects of BMY 14802, a selective sigma receptor "antagonist" and putative antipsychotic drug, and haloperidol on regional neurotensin concentrations in rat brain. North Carolina Society for Neuroscience, 35.

11. Levant B, Bissette G, Davis MD, Heffner TG, Nemeroff CB (1990) Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations. Soc. Neurosci. Abst., 16:250.

12. Levant B, Merchant KM, Dorsa DM, Nemeroff CB (1991) Haloperidol and sigma receptor ligand BMY 14802 increase regional brain neurotensin and proneurotensin mRNA concentrations. International Congress on Schizophrenia Research, Tuscon, AZ.

13. Levant B, Grigoriadis DE, DeSouza EB (1991) Characterization of [3H]quinpirole binding in rat striatum. Soc. Neurosci. Abst., 17:817.

14. Bissette G, Levant B, Banks B, Nemeroff CB (1991) Seasonal alterations in hypothalamic neurotensin concentrations. Soc. Neurosci. Abst., 17:1193.

15. Myers B, Levant B, Bissette G, Nemeroff CB (1991) Specificity of the increase in neurotensin concentrations after chronic antipsychotic drug treatment. Soc. Neurosci. Abst., 17:986.

16. Nemeroff CB, Bissette G, Levant B, Dorsa DM, Merchant KM (1991) The effects of antipsychotic drugs on regional CNS concentrations of neurotensin mRNA levels. Proc. 30th Ann. Mtg. Am. Coll. Neuropsychopharmacol., 10.

17. Levant B, Grigoriadis DE, De Souza EB (1992) Autoradiographic localization of [3H]quinpirole binding to putative D2 and D3 dopamine receptors in rat brain. Soc. Neurosci. Abst., 18:8.

18. Levant B, Grigoriadis DE, De Souza EB (1992) Autoradiographic localization of D3 dopamine receptors, a potential antipsychotic drug target: discrete population in cerebellum. Proc. 31st Ann. Mtg. Am. Coll. Neuropsychopharmacol., 68.

19. Levant B, Grigoriadis DE, De Souza EB (1993) D3 dopamine receptors, a potential antipsychotic drug target: identification and characterization of a discrete population in cerebellum. Schizophrenia Res., 9:242.

20. Levant B, Grigoriadis, DE, De Souza EB (1993) MAO inhibitors inhibit [3H]quinpirole binding in rat striatal membranes. Soc. Neurosci. Abst., 19:79.

21. Sahagan BG, Focht RJ, Conklin DS, Sperle K, Levant B, Turner MJ, Senick RS, Ebner S, Grigoriadis DE, Jonak J (1993) Overexpression of the human dopamine D3 receptor in the brain of transgenic mice. Soc. Neurosci. Abst., 19:1689.


22. Levant B, Grigoriadis DE, De Souza EB (1994) Relative potencies of dopaminergic compounds at [125I]iodosulpiride-labeled D2 and D3 receptors in rat brain. Can. J. Physiol. Pharmacol., 72(Suppl.1): 388.

23. Levant B (1994) Effects of sulfhydryl reagents and heavy metal cations on agonist binding to D2 and D3 dopamine receptors. Soc. Neurosci. Abst., 20:525.

24. Levant B (1994) Differential effects of EEDQ on D2 and D3 dopamine receptors. Proc. 33rd Ann. Mtg. Am. Coll. Neuropsychopharmacol., 195.

25. Levant B (1995) Effects of EEDQ on [3H]7-OH-DPAT-labeled receptors in rat ventral striatum. Gordon Research Conference on Catecholamines, Barga, Italy.

26. Levant B (1995) Differential sensitivity of [3H]7-OH-DPAT-labeled binding sites in rat brain to inactivation by EEDQ. Soc. Neurosci. Abst., 21:852.

27. Morgan KA, Moehlenkamp JD, Leonard NL, Cheng CC, Levant B (1995) Pharmacological characterization of MAO inhibitor interactions with [3H]quinpirole binding in rat brain. Soc. Neurosci. Abst., 21:856.

28. Moehlenkamp JD, Levant, B (1995) Monoamine oxidase inhibitor interactions with [3H]quinpirole binding in rat brain and peripheral organs. Soc. Neurosci. Abst., 21:856.

29. Levant B (1995) In vivo occupancy of D2 dopamine receptors by 7-OH-DPAT. Proc. 34th Proc. 31st Ann. Mtg. Am. Coll. Neuropsychopharmacol., 176.

30. Levant B, Morgan KA, Moehlenkamp JD (1996) A potential novel binding site for MAO inhibitors in brain. Biol. Psychiatry, 39:593.

31. Levant B, Bancroft GN (1996) Subcellular distribution and pharmacology of [3H]quinpirole and [3H]spiperone binding sites in rat brain. Soc. Neurosci, Abst., 22:827.

32. Flietstra RJ, Levant B (1996) Simultaneous comparison of D2/D3 receptor affinity of novel D3-selective drugs in rat brain. Soc. Neurosci, Abst., 22:827.

33. Levant B, Bancroft GN, Flietstra RJ (1996) Comparison of [3H]7-OH-DPAT and [3H]PD 128907 for the study of D3 dopamine receptors in rat brain. Proc. 35th Ann. Mtg. Am. Coll. Neuropsychopharmacol., 270.

34. Levant B, Bancroft GN, Selkirk CM, Vansell N (1997) In vivo occupancy of D2 dopamine receptors by D3 receptor-selective drugs. Schizophrenia Res., 24:79.

35. Cashman JR, Underiner, G, Xu L, Janowsky A, Levant B (1997) Cocaine antagonists form directed combinatorial chemistry. NIDA Research Monograph 175. Medication Development for the Treatment of Cocaine Dependence: Issues in Clinical Efficacy Trials. 175:77. http://views.vcu.edu/cpdd/97abs/ cashman.html.

36. Morgan KA, Levant B (1997) Autoradiographic localization of [3H]PD 128907 binding to putative D3 dopamine receptors in brain. Soc. Neurosci. Abst., 23:683.

37. Shafer RA, Levant B (1997) Fos protein expression is induced by nafadotride, a dopamine D3 receptor-preferring antagonist. Soc. Neurosci. Abst,. 23:682.

38. Levant B (1997) Up-regulation of D2, but not D3, dopamine receptors after chronic antipsychotic treatment. Soc. Neurosci. Abst., 23:683.

39. Tessel RE, Levant B, Loupe PS, Zhou X, Schroeder SR, Lunte S (1997) Antagonism of neonatal 6-OHDA-induced reductions in adult rat neostriatal DA transporter (DAT) and DA content by fixed-ratio discrimination training (FRDT). Soc. Neurosci. Abst,. 23:230.

40. Levant B, Morgan KA (1997) Autoradiographic distribution of putative D3 dopamine receptors in the brain of the rat and other mammalian species. Proc. 36th Ann. Mtg. Am. Coll. Neuropsychopharmacol., 165.

41. Levant B (1998) Differential distribution of dopamine D3 receptors in the brains of various mammalian species. Dopamine ‘98, Strasbourg, France.

http://views.vcu.edu/cpdd/97abs/


42. Levant B, Cross RS, Pazdernik TL (1998) Alterations in local cerebral glucose utilization produced by selective D3 dopamine receptor blockade. Soc. Neurosci. Abst., 24:855.

43. Gilliland SL, Alper RH, Levant B (1998) Characterization of quinpirole-stimulated [35S]GTPγS binding in rat striatal membranes. Soc. Neurosci. Abst., 24:597.

44. Levant B (1998) MAOIs: interactions at dopamine receptors? Proc. World Internet Congress ‘98. http://www.mcmaster.ca/inabis98/levant/levant0103/index.html.

45. Gilliland SL, Alper RH, Levant B (1998) Characterization of quinpirole-stimulated [35S]GTPgamma S binding at D2-like receptors in rat striatum. Proc. World Internet Congress ‘98. http://www.mcmaster.ca/ inabis98/neuropharm/gilliland0401/index.html.

46. Levant B, Pazdernik TL, Cross RS, Shafer RA (1998) Effects of D3 dopamine receptor stimulation or blockade on neuronal activity in specific brain regions: Fos expression and local cerebral glucose utilization studies. Proc. 37th Ann. Mtg. Am. Coll. Neuropsychopharmacol., 193.

47. Kuhn CM, Schwartz-Bloom RD, Rodriguez A, Cabassa J, Levant B (1998) Localization of the dopamine transporter in basal ganglia of male and female rats. Proc. 37th Ann. Mtg. Am. Coll. Neuropsycho-pharmacol., 292.

48. Levant B (1999) Neurobiology of the D3 dopamine receptor. Behav. Pharmacol., 10 (Suppl. 1):S57.

49. Levant B, Garimelli B, Shafer RA, Merchant KM (1999) Increased levels of proneurotensin/ neuromedin N mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride. Soc. Neurosci. Abst., 25:1468.

50. Levant B, Gilliland SL, Morgan KA, Alper RH (1999) Dopamine-receptor agonist-stimulated [35S]GTPγS binding in rat striatal membranes: additive effects of D1-like and D2-like agonists. Proc. 38th Ann. Mtg. Am. Coll. Neuropsychopharmacol., 197.

51. Levant B, Morgan KA, Grandy DK, Shih JC, Chen K, Seif I (2000) Modulation of [3H]quinpirole binding to D2 dopamine receptors by a MAO-A-like site?. Soc. Neurosci. Abst., 26:1419.

52. Levant B, McCarson KE (2000) D3 dopamine receptors in rat spinal cord: implications for sensory and motor function. Proc 39th Ann. Mtg. Am. Coll. Neuropsychopharmacol., 222.

53. Levant B, McCarson KE (2001) D3 dopamine receptors in rat spinal cord: implications for sensory and motor function. Soc. Neurosci. Abst., 27:379.15.

54. Levant B, Pazdernik TL (2001) Alterations in local cerebral glucose utilization produced by ibogaine, a putatively anti-addictive drug. Proc 40th Ann. Mtg. Am. Coll. Neuropsychopharmacol.,115.

55. Albright TJ, Pazdernik TL, Levant B (2002) Effects of ibogaine, a putatively anti-addictive drug, on local cerebral glucose utilization. Experimental Biology 2002, 452.8.

56. Richtand NM, Welge JA, Levant B, Hayes SA, Logue AD, Striako M, Pritchard L, Berger SP, Coolen LM (2002) D3 dopamine receptor function is decreased following behavioral sensitization to amphetamine. Biol. Psychiatry 51:40S.

57. Levant B, Radel JD, Richards TL, Grasing K, Carlson SE (2002) Effects of developmental DHA deficiency and remediation on adult behavior in rats. Soc. Neurosci. Abst., 32:106.4.

58. Radel JD, Levant B, Carlson SE (2002) Effects of developmental DHA deficiency and remediation upon evoked brain activity at maturity in rats. Soc. Neurosci. Abst., 32:106.5.

59. Richards TL, Pazdernik TL, Levant B (2002) Differences in quinpirole-induced local cerebral glucose utilization in naïve and sensitized rats. Soc. Neurosci. Abst., 32:879.19.

60. Richtand NM, Welge JA, Levant B, Logue AD, Hayes SA, Ostrander M, Pritchard L (2002) Altered behavioral response to dopamine D3 receptor agonist following repetitive amphetamine treatment. Soc. Neurosci. Abst., 32:400.16.

http://www.mcmaster.ca/


61. Levant B, Radel JD, Carlson SE (2002) Developmental DHA deficiency alters adult behavior in rats. Reversal by dietary remediation. Proc. 41th Ann. Mtg. Am. Coll. Neuropsychopharmacol.

62. Levant B, Radel JD, Richards TL, Grasing K, Carlson SE (2003) Effects of developmental DHA deficiency and remediation on adult behavior in rats. Kansas City Life Sciences Day., March 27, 2003.

63. Levant B, Radel JD, Carlson SE (2003) Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation. Maternal and Infant LCPUFA Workshop, American Oil Chemists Society. May 3-4, 2003.

64. Radel JD, Levant B, Carlson SE (2003) Correlation of altered evoked neural activity at maturity and brain DHA levels during early development: A reversibility study in rats. Maternal and Infant LCPUFA Workshop,American Oil Chemists Society. May 3-4, 2003.

65. Gaines, J, Levant B, Radel J, Carlson SE (2003) Midbrain Gene Expression in a Rat Model of “Physiologically-Relevant” DHA Reduction. Maternal and Infant LCPUFA Workshop, American Oil Chemists Society. May 3-4, 2003.

66. Levant B, Pazdernik TL (2003) Differential effects of ibogaine on local cerebral glucose utilization in drug-naive and morphine-addicted rats. Soc. Neurosci. Abst., 33:645.1.

67. Carpenter TL, Levant B (2003) Differential protein expression profile in subcellular fractions of rat brain. Soc. Neurosci. Abst., 33:965.1.

68. Miller CC, Levant B, Radel JD, Carlson SE (2004) Decreased brain DHA during development alters sucrose drinking in adult male rats. Brain Uptake and Utilization of Fatty Acids, Lipids and Lipoproteins Meeting, Bethesda, MD, October 7-9, 2004.

69. Levant B, Radel JD, Carlson SE (2004) Reduced brain DHA content after a single reproductive cycle in female rats on a diet deficient in α-linolenic acid. Brain Uptake and Utilization of Fatty Acids, Lipids and Lipoproteins Meeting, Bethesda, MD, October 7-9, 2004.

70. Levant B, Radel JD, Carlson SE (2004) Reduced brain DHA content after a single reproductive cycle in female rats on a diet deficient in α-linolenic acid. Soc. Neurosci. Abst., 34:570.14.

71. Richards TL, Pazdernik TL, Levant B (2004) Differences in quinpirole-induced local cerebral glucose utilization in anterior cortical brain areas in drug-naïve and quinpirole-sensitized rats. Soc. Neurosci. Abst., 34:803.15.

72. Witkin JM, Levant B, Zapata A, Kaminski R, Dijkstra D, Akunne H, Peters S, Shannon H, Gasior M (2004) Dopamine D3 receptors may regulate dopaminergic toxicity. Neuropsychopharmacolog,y 29, suppl. 1:S18

73. Levant B, Crane JF, Carlson SE (2005) Sub-chronic treatment with antipsychotic drugs does not alter brain phospholipid fatty acid composition in rats. Soc. Neurosci. Abst. Program No. 1023.4. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

74. Richtand NM, Levant B, Taylor B, Ahlbrand R, Lu A, McNamara RK (2005) Reduced dopamine D3 receptor-mediated inhibition in C57BL/6J mice compared with DBA/2J mice. Soc. Neurosci. Abst. Program No. 681.16. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

75. Frost SB, Levant B, Richards TL, Barbay S, Dancause N, Friel NM, Stowe AM, Zoubina EV, Plautz EJ, Nudo RJ (2005) Receptor density changes in motor cortical areas following infarct in primary motor cortex. Soc. Neurosci. Abst. Program No. 900.9. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

76. Richards TL, Pazdernik TL, Levant B (2005) Clorgyline-induced modification of behavioral sensitization to quinpirole: effects on local cerebral glucose utilization. Soc. Neurosci. Abst. Program No. 681.6. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.


77. Ozias MK, Carlson SE, Levant B (2005) Effects of sex and brain docosahexaenoic acid content on locomotor activity in immature rats. Soc. Neurosci. Abst. Program No. 679.15. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

78. Radel JD, Carlson SE, Levant B (2005) Transmitter receptor binding in cortex altered by dietary fatty acid availability during development. Soc. Neurosci. Abst. Program No. 956.11. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

79. Levant B, Radel JD, Carlson SE (2005) Reduced brain docosahexaenoic acid content after a single reproductive cycle in female rats maintained on a diet deficient in n-3 polyunsaturated fatty acids. Neuropsychopharmacology, 30:S177.

80. McNamara RK, Levant B, Taylor B, Ahlbrand R, Liu A, Stanford K, Richtand NM (2005) Sensitization-prone C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated inhibition relative to sensitization-resistant DBA/2J mice. Neuropsychopharmacology, 30:S212.

81. Richards TL, Pazdernik TL, Levant B (2006) Clorgyline-induced modification of behavioral sensitization to quinpirole: effects on behavior and local cerebral glucose utilization. Experimental Biology 2006, 434.8.

82. Levant B, Ozias MK, Carlson SE (2006) Maternal parity influences the effects of an α-linolenic acid diet on maternal and offspring brain docosahexaenoic acid content. International Society for the Study of fatty Acids and Lipids, Cairns, Australia, July 23-28, 2006.

83. McNamara RK, Richtand NM, Levant B (2006) Omega-3 fatty acid deficiency decreases dopamine D2 receptor binding and increases serotonin 5-HT2A receptor binding in adult rat prefrontal cortex. Biol. Psychiatry, 59: S146.

84. Levant B, Ozias MK, Jones KA, Carlson SE (2006) Differential effects of modulation of brain docosahexaenoic acid content during development in specific brain regions in rat. Soc. Neurosci. Abst. 97.1. 2006 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

85. Davis PF, Ozias MK, Radel JD, Carlson SE, Levant B (2006) Depletion of maternal brain docosahexaenic acid: differential effects in specific brain regions. Soc. Neurosci. Abst. 288.12. 2006 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

86. Ozias MK, Carlson SE, Levant B (2006) Maternal parity and diet influence offspring brain docosahexanoic acid content. Soc. Neurosci. Abst. 97.2. 2006 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

87. Richards TL, Fowler SC, Levant B (2006) Quinpirole-induced sensitization of locomotor activity is transformed into focused stereotypy by clorgyline pretreatment. Soc. Neurosci. Abst. 689.21. 2006 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

88. Ozias MK, McCarson KE, Levant B (2007) Depletion of brain docosahexaenoic acid content and reproductive status affects brain-derived neurotrophic factor expression in the female rat. Soc. Neurosci. Abst. 907.20. 2007 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

89. Davis PF, Levant B (2007) Depletion of brain docosahexaenoic acid content and reproductive status affects dopamine and serotonin receptor binding in the female rat. Soc. Neurosci. Abst. 907.22. 2007 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

90. Levant B, McCarson KE (2007) Reduced brain docosahexaenoic acid content alters hippocampal BDNF gene expression and 5-HT1A receptor binding in female rats: effects of reproductive status. American College of Neuropsychopharmacology, Boca Raton, FL, Dec. 8-12, 2007.

91. McNamara RK, Able J, Richtand NM, Levant B (2007) Chronic risperidone has reduced efficacy in omega-3 fatty acid deficient rats. American College of Neuropsychopharmacology, Boca Raton, FL, Dec. 8-12, 2007.

92. Levant B, Carlson SE, McCarson KE (2008) Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. International Society for the Study of fatty Acids and Lipids, Kansas City, MO, May 17-22, 2008.


93. Ahmad SO, Park J-H, Radel JD, Levant B (2008) Reduced numbers of dopamine neurons in the substantia nigra pars compactaand ventral tegmental area of rats fed an n-3 polyunsaturated fatty acid-deficient diet: A stereological study. Soc. Neurosci. Abst. 122.10. 2008 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

94. Levant B, Reed GA, Carlson SE (2008) Dopamine receptor alterations in female rats with decreased brain omega-3 DHA: interactions with reproductive status. American College of Neuropsychopharmacology, Scottsdale, AZ, Dec. 7-11, 2008.

95. Fowler SC, Zarcone TJ, Levant B (2009) Effects of methylphenidate on rats’ responses to the introduction of a novel spatial stimulus into a familiar environment. Behavioral Pharmacology Society. New Orleans, LA, April 18, 2009.

96. Levant B, Zarcone TJ, Fowler SC (2009) Dietary omega-3 fatty acid content and age affect activity and response to novelty in rats. Soc. Neurosci. Abst. 122.10. 2009 Abstract Viewer/Itinerary Planner. Chicago, IL: Society for Neuroscience. Online.

97. Raveendran V, Tan X, Levant B, Stechschulte DJ, Dileepan KN (2010) Lipopolysaccharide induces H1 receptor expression and enhances histamine responsiveness in human coronary artery endothelial cells. American Association of Immunologists’ Meeting, May 7-12, 2010, Baltimore, MD.

98. Levant B, Zarcone TJ, Fowler SC (2010) Effects of dietary n-3 fatty acids and brain DHA content on activity and response to novelty in the developing rat. International Society for the Study of fatty Acids and Lipids, Maastricht, The Netherlands, May 29-June 2, 2010.

99. Raveendran V, Tan X, Levant B, Stechschulte DJ, Dileepan KN (2010) Lipopolysaccharide enhances histamine responsiveness in human coronary artery endothelial cells by stimulating the expression of H1 receptors. 14th International Congress of Immunology, Kobe, Japan, August 22-27, 2010.

100. Levant B, Zarcone TJ, Fowler SC (2010) Age differences in methylphenidate dose-response in rats in a test of activity and response to spatial novelty. Soc. Neurosci. Abst.. 168.16 2010 Abstract Viewer/Itinerary Planner. San Diego, CA: Society for Neuroscience. Online.

101. Russell KL, Berman NEJ, Levant B (2010) Evaluation of sensorimotor behavioral tests for assessment of recovery after juvenile traumatic brain injury in a rodent model. Soc. Neurosci. Abst.. 467.3 2010 Abstract Viewer/Itinerary Planner. San Diego, CA: Society for Neuroscience. Online.

102. Oien DB, Ortiz AN, Dobrowksy RT, Johnson MA, Levant B, Fowler SC, Moskovitz J (2010) Dopamine D2 receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse. Soc. Neurosci. Abst.. 146.16 2010 Abstract Viewer/Itinerary Planner. San Diego, CA: Society for Neuroscience. Online.

103. Russell KL, Berman NEJ, Levant B (2011) Dietary n-3 fatty acid content influences sensorimotor outcomes after TBI in juvenile rats. National Neurotrauma Symposium, Ft. Lauderdale FL, July 13-17, 2011.

104. Russell KL, Berman NEJ, Levant B (2011) Effects of dietary N-3 fatty acid content on sensorimotor outcomes in a rat model of juvenile traumatic brain injury. Soc. Neurosci. Abst.. 462.12 2011 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

105. Healy Stoffel M, Ahmad SO, Stanford JA, Levant B (2011) Effects of a partial unilateral striatal 6-hydroxydopamine lesion of dopamine cell number and volume in the substantia nigra pars compacta: a stereological study utilizing tyrosine hydroxylase and silver nucleolar stains. Soc. Neurosci. Abst.. 244.01 2011 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

106. Levant B, Russell KL, Berman NEJ (2012) Effects of diet-induced decreases in brain DHA content on outcomes in a rat model of juvenile traumatic brain injury. International Society for the Study of fatty Acids and Lipids, Vancouver, BC, Canada, May 26-30, 2012.


107. Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B (2012) Changes in nucleolar morphology in substantia nigra dopamine neurons following unilateral intrastriatal 6-hydroxydopamine in rats. Soc. Neurosci. Abst.. 709.11 2012 Abstract Viewer/Itinerary Planner. New Orleans, LA: Society for Neuroscience. Online.

108. Russell KL, Berman NEJ, Levant B (2012) Altered expression of injury response mediators after TBI in juvenile rats with decreased brain omega-3 DHA content. Soc. Neurosci. Abst.. 864.02 2012 Abstract Viewer/Itinerary Planner. New Orleans, LA: Society for Neuroscience. Online.

109. Levant B, Guilford BL, Wright DE (2013) Alterations in brain lipid composition induced by a high-fat diet and diabetes in mice. AD/PD 2013. Florence, Italy, March 6-10, 2013.

110. Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B (2013) Changes in nucleolar morphology in substantia nigra dopamine neurons following unilateral intrastriatal 6-hydroxydopamine in rats. AD/PD 2013. Florence, Italy, March 6-10, 2013.

111. Ahmad SO, Healy-Stoffel M, Stanford JA, Levant B (2013) Differentially altered neuronal number and morphology in midbrain dopaminergic subregions after a unilateral intrastriatal 6-OHDA lesion. Soc. Neurosci. Abst.. 623.03 2013 Abstract Viewer/Itinerary Planner. San Diego, CA: Society for Neuroscience. Online.

112. Levant B (2015) Effects of decreased Omega-3 DHA in the adult brain: Implications for depression. International Behavioral Neuroscience Society. Victoria, BC, Canada, June 2-6, 2015.

Invited Presentations:

1. DuPont Pharmaceuticals & Biotechnology R&D, Wilmington, DE, November, 1990. Modulation of regional brain neurotensin concentrations by antipsychotic drugs: focus on sigma receptors.

2. Burroughs Wellcome Company, Research Triangle Park, NC, May 1992. Biochemical and autoradiographic characterization of [3H]quinpirole binding to dopamine receptors: applications for the visualization of a novel site for antipsychotic drug action.

3. Gensia Pharmaceutical Company, San Diego, CA, July 1992. [3H]Quinpirole binding to novel dopamine receptors: applications for the visualization of a potential site for antipsychotic drug action.

4. 31st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, December, 1992. Autoradiographic localization of D3 dopamine receptors, a potential antipsychotic drug target: discrete population in cerebellum.

5. Department of Pharmacology, University of Kansas Medical Center, Kansas City, KS, January, 1993. [3H]Quinpirole binding to novel dopamine receptors: visualization of a potential site for antipsychotic drug action.

6. Department of Pharmacology, University of Rochester, Rochester, NY, January, 1993. [3H]Quinpirole binding to novel dopamine receptors: visualization of a potential site for antipsychotic drug action.

7. Upjohn Pharmaceutical Company, Kalamazoo, MI, January, 1993. [3H]Quinpirole binding to novel dopamine receptors: visualization of a potential site for antipsychotic drug action.

8. Department of Psychiatry, University of Wisconsin-Madison School of Medicine, Madison, WI, March, 1993. [3H]Quinpirole binding to novel dopamine receptors: visualization of a potential site for antipsychotic drug action.

9. Neuroscience Society, Kansas City Chapter, Kansas City, KS, October, 1993. Autoradiographic studies of novel dopamine receptors.

10. Division of Pharmacology, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, November, 1994. Comparative studies of D2 and D3 dopamine receptors.


11. Department of Neurology, University of Kansas Medical Center, Kansas City, KS, March, 1995. Novel dopamine receptors in neuropsychiatric disorders.

12. Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS, October, 1995. Localization and characterization of D3 dopamine receptors, a potential antipsychotic target.

13. Department of Pharmacology, University of Kansas Medical Center, Kansas City, KS, January, 1997. Monoamine oxidase inhibitors: interactions with dopamine receptors?

14. Sigma Xi, University of Kansas Medical Center Chapter, Kansas City, KS, October, 1997. Monoamine oxidase inhibitor interactions at dopamine receptors OR Can old drugs do new tricks?

15. Department of Pharmacology, Rush University School of Medicine, Chicago, IL, January, 1998. Localization and function of D3 dopamine receptors.

16. INABIS ‘98: 5th World Internet Congress on Biomedical Sciences, December, 1998. MAOIs: interactions at dopamine receptors?

17. DuPont Pharmaceuticals, Wilmington, DE, January, 1999. Neurobiology of the D3 dopamine receptor, a potential antipsychotic target.

18. Pfizer Central Research, Groton, CT, January, 1999. Neurobiology of the D3 dopamine receptor, a potential antipsychotic target.

19. First International Meeting of the Behavioral Pharmacology Society and European Behavioral Pharmacology Society, Boston, MA, September, 1999. Neurobiology of the dopamine D3 receptor.

20. Division of Pharmacology, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, October, 1999. The D3 dopamine receptor: neurobiology and relevance in neuropsychiatric disorders.

21. Workshop on Pharmacogenetics of Drug Therapy. University of British Columbia, Vancouver, BC, November, 1999. Dopamine receptor heterogeneity: neurobiology and therapeutic implications.

22. Department of Pharmacology, University of Kansas Medical Center, Kansas City, KS, January, 2000. D3 dopamine receptor-”preferring” compounds: pharmacological effects and specificity.

23. National Institute on Drug Abuse, Baltimore, MD, February, 2000. D3 dopamine receptor-“preferring” compounds: pharmacological effects and specificity.

24. Department of Pharmacology, University of Health Sciences, Kansas City, MO, March, 2000. The D3 dopamine receptor: neurobiology and potential clinical relevance.

25. Center on Aging, University of Kansas Medical Center, Kansas City, KS, April, 2000. The D3 dopamine receptor: neurobiology and relevance in neuropsychiatric disorders.

26. Kansas City Veterans Administration Medical Center, Kansas City, MO, June, 2000. MAOIs: interactions at dopamine receptors?

27. Aventis Pharmaceuticals, Bridgewater, NJ, June, 2001. D3 dopamine receptor-“preferring” compounds: pharmacological effects and specificity.

28. Department of Biology, Elon University, Elon, NC, September, 2001. Pharmacology and Toxicology.

29. Department of Biology, Elon University, Elon, NC, September, 2001. Issues of solubility in drug action.

30. Department of Biology, Elon University, Elon, NC, September, 2001. Drugs acting on ion channels and transporters.

31. Department of Pharmacology, University of Michigan, Ann Arbor, MI, February, 2003. Biochemical Pharmacology of D3 Dopamine Receptors.

32. Maternal and Infant LCPUFA Workshop, American Oil Chemists Society, Kansas City, MO, May, 2003. Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation.


33. Department of Physiology, University of Kansas Medical Center, Kansas City, KS, April, 2004. PUFAs and mental health.

34. Department of Psychiatry, University of Kansas Medical Center, Kansas City, KS, November, 2004. PUFAs and mental health.

35. Department of Pharmacology, University of Kansas Medical Center, Kansas City, KS, April, 2005. PUFAs and mental health.

36. Department of Dietetics and Nutrition 2005 Clinical Nutrition Seminar. University of Kansas Medical Center, Kansas City, KS, September, 2005. Brain DHA: potential role in neuropsychiatric disorders.

37. Department of Pharmacology, University of Kansas Medical Center, Kansas City, KS, March, 2006. Modulation of brain PUFA composition OR Are you what you eat?

38. International Society for the Study of Fatty Acids and Lipids. Cairns, Australia, July, 2006. Maternal parity influences the effects of an α-linolenic acid-deficient diet on maternal and offspring brain docosahexaenoic acid contents.

39. Hill’s Science and Technology Center. Topeka, KS, August, 2006. PUFAs and Maternal and Infant Health.

40. Sigma Xi, University of Kansas Medical Center Chapter, Kansas City, KS, October, 2006. Neural Function and Diet – Defining a Role for DHA in Early Brain Development.

41. Department of Pharmacology, University of Kansas Medical Center, Kansas City, KS, February, 2007. Depletion of maternal brain docosahexaenoic acid content: a contributing factor in postpartum depression?

42. Neuroscience Colloquium, University of Kansas, Lawrence, KS, February, 2008. Decreased brain omega-3 DHA content produces neurobiological effects associated with depression: interactions with reproductive status in female rats.

43. Department of Physiology, University of Kansas Medical Center, Kansas City, KS, May, 2008. Decreased brain omega-3 DHA content produces neurobiological effects associated with depression: interactions with reproductive status in female rats.

44. International Society for the Study of Fatty Acids and Lipids. Kansas City, MO, May, 2008. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats.

45. Department of Psychiatry, University of Kansas Medical Center, Kansas City, KS, September, 2008. Decreased brain omega-3 DHA produces neurobiological effects associated with depression: interactions with reproductive status in female rats.

46. Women in Medicine and Science. University of Kansas Medical Center, Kansas City, KS, October, 2008. DHA, brain development, and activity: effects in a rat model.

47. Department of Pharmacology, University of North Texas Health Sciences Center. Fort Worth, TX, February, 2009. Decreased brain omega-3 DHA produces neurobiological effects associated with depression: interactions with reproductive status in female rats.

48. International Society for the Study of Fatty Acids and Lipids. Maastricht, The Netherlands, May, 2010. Effects of dietary n-3 fatty acids and brain DHA content on activity and response to novelty in the developing rat.

49. Institute for Neurological Disorders, University of Kansas Medical Center, Kansas City, KS, April, 2011. Effects of alterations in DHA in the adult brain: Implications for depression.

50. West Virginia School of Osteopathic Medicine. Lewisburg, WV, May, 2011. Pharmacological treatment of depression.


51. Western New England University School of Pharmacy, Springfield, MA, December, 2011. Effects of alterations in Omega-3 DHA in the adult brain: Implications for depression.

52. St. Louis University, Doisy College of Health Sciences, January, 2012. Effects of alterations in Omega-3 DHA in the adult brain: Implications for depression.

53. International Society for the Study of Fatty Acids and Lipids. Vancouver, BC, Canada, May, 2012. Effects of diet-induced decreases in brain DHA content on outcomes in a rat model of juvenile traumatic brain injury.

54. Department of Pharmacology, A.T.Still University, Kirksville, MO, March, 2013. Effects of alterations in Omega-3 DHA in the adult brain: Implications for depression.

55. Department of Chemistry, Wichita State University, Wichita, KS, October, 2014. Effects of alterations in Omega-3 DHA in the adult brain: Implications for depression.

56. International Behavioral Neuroscience Society Meeting. Victoria, BC, Canada, June, 2015. Effects of decreased Omega-3 DHA in the adult brain: Implications for depression.

Patents:

1. Wang S., Chen J, Collins GT, Woods J, Levant B, Selective ligands for the dopamine 3 (D3) receptor and methods of using the same, U.S. Patent No. 8,238,368.

2. Wang S., Chen J, Collins GT, Levant B, Woods JH, Selective ligands for the dopamine 3 (D3) receptor and methods of using the same, U.S. Patent No. 8,486,981.

beth levant, ph.d., m.p.a.wichita.kumc.edu/documents/pharmacology/faculty/levant...beth levant,...

Documents